Comparative Pharmacology
Head-to-head clinical analysis: IOBENGUANE I 123 versus JAYPIRCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOBENGUANE I 123 versus JAYPIRCA.
IOBENGUANE I-123 vs JAYPIRCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iobenguane I-123 is a radiopharmaceutical analog of norepinephrine that is taken up by adrenergic neurons and neuroendocrine tumors via the norepinephrine transporter (NET). It localizes in tissues rich in sympathetic innervation and tumors expressing NET, enabling scintigraphic imaging.
JAYPIRCA (pirtobrutinib) is a selective, non-covalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). It binds to BTK, inhibiting its kinase activity, thereby blocking B-cell receptor signaling and reducing proliferation and survival of malignant B cells.
Intravenous administration of 5 mCi (185 MBq) as a single dose for imaging.
The recommended adult dose is 15 mg orally once daily, with or without food.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours; clinically relevant for imaging timing (optimal scanning at 24 hours post-injection)
Terminal half-life approximately 15-20 hours in adults with normal renal function; prolonged in renal impairment (up to 30-40 hours in severe impairment).
Renal: 40-60% as unchanged iobenguane within 24 hours; biliary/fecal: minimal (<5%)
Primarily renal (80-90% as unchanged drug and minor metabolites); fecal <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical